valsartan has been researched along with Neointima in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, X; Guo, J; Li, Y; Liu, X; Peng, L; Sun, T; Tang, X; Xu, Q; Yang, X; Yu, H; Zhou, J | 1 |
| Cai, S; Li, Y; Liu, X; Ren, B; Sun, T; Wang, Q; Xu, Q; Yu, H; Zhou, J | 1 |
| Furuno, M; Higaki, J; Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Okayama, H; Senba, I | 1 |
| Ahn, CM; Choi, SC; Hong, SJ; Kim, JS; Lim, DS; Park, JH | 1 |
1 trial(s) available for valsartan and Neointima
| Article | Year |
|---|---|
Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
Topics: Adiponectin; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Coronary Stenosis; Diabetes Mellitus, Type 2; Disease Progression; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hypertension; Interleukin-6; Male; Middle Aged; Neointima; Prospective Studies; Single-Blind Method; Sirolimus; Telmisartan; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography, Interventional; Valine; Valsartan | 2011 |
3 other study(ies) available for valsartan and Neointima
| Article | Year |
|---|---|
Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4-iNOS-ERK-AT1 Receptor Pathway in the Balloon-injured Rat Aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Hyperplasia; Male; Neointima; Nitric Oxide Synthase Type II; Phosphorylation; Rats, Wistar; Receptor, Angiotensin, Type 1; Serine-Arginine Splicing Factors; Signal Transduction; Toll-Like Receptor 4; Valsartan; Vascular System Injuries | 2021 |
Valsartan decreases neointimal hyperplasia in balloon-injured rat aortic arteries by upregulating HO-1 and inhibiting angiotensin II type 1 receptor.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Animals; Aorta, Thoracic; Bilirubin; DNA Primers; Gene Expression Regulation; Heme Oxygenase-1; Hyperplasia; Male; Neointima; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan | 2014 |
Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Arteries; Blood Vessels; Disease Models, Animal; Hydralazine; Hypertension; Mice; Mice, Inbred C57BL; NADPH Oxidases; Neointima; Oxidative Stress; Renin; Tetrazoles; Valine; Valsartan | 2011 |